We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Trials and tribulations

27 Jul 2017 By John Foley

A cancer treatment failed to live up to high hopes, wiping as much as $14 billion off the company’s value. The outlook for the UK drugmaker and its boss Pascal Soriot is suddenly more uncertain. But there are other areas of growth – and Astra is now an easier takeover target.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)